Literature DB >> 3653232

Bioavailability of disopyramide in normal volunteers using unbound concentration.

J Braun1, F Sörgel, W P Gluth, S Oie.   

Abstract

The pharmacokinetics of disopyramide were determined in 10 healthy volunteers after a 300 mg oral dose and again after a 2 mg/kg i.v. dose. The unbound clearance was 599 ml/min and the unbound renal clearance 310 ml/min. The terminal elimination rate constant of unbound drug was 0.180 h-1 after the i.v. dose and 0.203 h-1 after the oral dose. The absorption rate constant was 0.53(-1) and the maximum peak concentration occurred after 3.2 h. The bioavailability was 0.809 using the area under the unbound plasma concentration time curve. Although a saturable plasma protein binding was found in all subjects the bioavailability using the total concentration, in contrast to theoretical expectations, showed the same value (0.813) as the unbound concentrations.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3653232     DOI: 10.1007/BF02456000

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans.

Authors:  P H Hinderling; E R Garrett
Journal:  J Pharmacokinet Biopharm       Date:  1976-06

3.  Role of concentration-dependent plasma protein binding in disopyramide disposition.

Authors:  P J Meffin; E W Robert; R A Winkle; S Harapat; F A Peters; D C Harrison
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

4.  Effect of saturable binding on the pharmacokinetics of drugs: a simulation.

Authors:  S Oie; T W Guentert; T N Tozer
Journal:  J Pharm Pharmacol       Date:  1980-07       Impact factor: 3.765

5.  Volume shifts and protein binding estimates using equilibrium dialysis: application to prednisolone binding in humans.

Authors:  T N Tozer; J G Gambertoglio; D E Furst; D S Avery; N H Holford
Journal:  J Pharm Sci       Date:  1983-12       Impact factor: 3.534

6.  Pharmacokinetic-pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man.

Authors:  M Thibonnier; N H Holford; R A Upton; C D Blume; R L Williams
Journal:  J Pharmacokinet Biopharm       Date:  1984-12

7.  Comparison of electrocardiographic response and disposition of R- and S-disopyramide in the rabbit.

Authors:  J D Huang; S Oie
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1983-08

8.  Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide.

Authors:  J J Lima; D B Haughey; C V Leier
Journal:  J Pharmacokinet Biopharm       Date:  1984-06

9.  Characterization of a common binding site for basic drugs on human alpha 1-acid glycoprotein (orosomucoid).

Authors:  W E Müller; A E Stillbauer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-03       Impact factor: 3.000

10.  Liquid-chromatographic determination of antidysrhythmic drugs: procainamide, lidocaine, quinidine, disopyramide, and propranolol.

Authors:  P M Kabra; S H Chen; L J Marton
Journal:  Ther Drug Monit       Date:  1981       Impact factor: 3.681

View more
  2 in total

Review 1.  Saturable pharmacokinetics in the renal excretion of drugs.

Authors:  C A van Ginneken; F G Russel
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

2.  Does alpha 1-acid glycoprotein reduce the unbound metabolic clearance of disopyramide in patients with renal impairment?

Authors:  J Braun; F Sörgel; W P Gluth; S Oie
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.